NCT03039218 is a NA clinical trial of Dornier Aries 2 in Erectile Dysfunction, sponsored by Dornier MedTech Systems.

Who is sponsoring NCT03039218?

NCT03039218 is sponsored by Dornier MedTech Systems.

What drugs are being tested in NCT03039218?

Interventions in NCT03039218: Dornier Aries 2, Placebo / Sham.

What condition does NCT03039218 study?

NCT03039218 studies Erectile Dysfunction.

Is NCT03039218 still recruiting?

NCT03039218 is currently terminated. Last updated 17 August 2018.

Last reviewed 2018-08-17 · How we verify

NCT03039218

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dornier Aries 2 Extracorporeal Shock Wave Device for the Treatment of Mild Erectile Dysfunction (ED)

Terminated NA Last updated 17 August 2018

What this trial tests

NA trial testing Dornier Aries 2 in Erectile Dysfunction in 54 participants. Terminated before completion.

Timeline

7 February 2017

Primary endpoint
29 March 2018

29 March 2018

Quick facts

Lead sponsor	Dornier MedTech Systems
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	54
Start date	7 February 2017
Primary completion	29 March 2018
Estimated completion	29 March 2018
Sites	4 locations across United States

Drugs / interventions tested

Dornier Aries 2
Placebo / Sham

Conditions studied

Erectile Dysfunction — all drugs for Erectile Dysfunction →

Sponsor

Dornier MedTech Systems

Who can join

Adults 22 to 70, male only, with Erectile Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This protocol allows for treatment of 100 men in two groups (placebo and active treatment) of 22-70 years of age with mild (IIEF EF of 17 to 25 at baseline) vasculogenic erectile dysfunction of at least 6 months duration with low intensity extracorporeal shock wave therapy utilizing the Dornier Aries 2 device.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Erectile Dysfunction

Currently open trials in the same condition.

NCT07442396 — The Effectiveness of Exercise in the Treatment of Erectile Dysfunction and Premature Ejaculation · NA · recruiting
NCT07366970 — Is There a Benefit From Addition of Exercise in Diabetic Patients With ED Who Complain Low Vitamin D? · NA · recruiting
NCT06960746 — Changing Lifestyle in OSA Males Who Suffer Metabolic Syndrome and Impotence: Is There a Response? · NA · recruiting
NCT06872866 — The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under · Phase 1 · recruiting
NCT06805513 — Actual Use Trial of Tadalafil 5 mg · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03039218 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dornier MedTech Systems
Last refreshed: 17 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03039218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing